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NC-ND license (http://creativecommoSummary Background: Hepatocellular carcinoma (HCC) is a common malignant disease of
the liver in China and Japan. The purpose of this study was to compare the outcomes of
HCC patients after hepatectomy between two regional medical centers in China and Japan.
Methods: Data on HCC after hepatectomy were collected from January 2005 to December 2014
from Nagasaki University Hospital in Nagasaki, Japan and the Second Affiliated Hospital of Nan-
chang University in Nanchang, China. The patient and tumor characteristics, HCC etiology, and
overall survival rates after hepatectomy were investigated.
Results: Two hundred patients in the Nagasaki group and 238 patients in the Nanchang group
were diagnosed with HCC and underwent hepatectomy. The major underlying liver diseases
were hepatitis C infection (32%, 64/200) and nonalcoholic steatohepatitis (NASH) (34.5%,
69/200) in the Nagasaki group, while in the Nanchang group, hepatitis B infection (79.4%,
189/238) was the dominant etiology. Large tumors (> 5 cm), the presence of a tumor capsule
and a high alpha-fetoprotein value ( 400 U/L) were more frequently observed in the Nan-
chang group as compared with the Nagasaki group (p < 0.05). According to an outcome anal-
ysis, the Nanchang patients showed worse survival rates as compared with Nagasaki patients,ave no conflicts of interest relevant to this article.
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two regional medical centers in Chinparticularly those with American Joint Committee on Cancer stages I and III due to the aggres-
sive character of HCC in the Nanchang group.
Conclusion: There are significant differences in the clinicopathologic features and outcomes of
HCC patients from Japan and China. These differences may impact the eligibility for poten-
tially curative therapy and the prognosis of patients with HCC.
Copyright ª 2016, Asian Surgical Association. Published by Elsevier Taiwan LLC. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Table 1 Comparison of clinicopathologic characteristics.
Variable Nagasaki
group
(n Z 200)
Nanchang
group
(n Z 238)
p
Gender 0.006
Male 153 (76.5) 206 (86.6)
Female 47 (23.5) 32 (13.4)
Age (y) <0.001
Mean  SD 68  10.7 52  12.7
Range 31e90 17e82
Underlying liver disease <0.001
HBV 52 (26) 189 (79.4)
HCV 64 (32) 0
NASH 69 (34.5) 14 (5.9)
Alcohol 12 (6) 1 (0.4)
HBV-HCV 1 (0.5) 1 (0.4)
HBV-Alcohol 1 (0.5) 33 (13.9)
HCV-Alcohol 1 (0.5) 0
Child-Pugh 0.809
A 188 (94) 225 (94.5)
B 12 (6) 13 (5.5)
C 0 0
AFP level distribution
(ng/mL)
<0.001
400 165 (82.5) 141 (59.2)
>400 35 (17.5) 97 (40.8)
Tumor size (cm) <0.001
5 148 (74) 115 (48.3)
>5 52 (26) 123 (51.7)
Tumor numbers 0.018
3 197 (98.5) 224 (94.1)
>3 3 (1.5) 14 (5.9)
Tumor capsule <0.001
Present 146 (73) 213 (89.5)
Absent 54 (27) 25 (10.5)
Vascular invasion <0.001
Present 41 (20.5) 20 (8.4)
Absent 159 (79.5) 218 (91.6)1. Introduction
Primary liver cancer is the sixth most frequent malignancy
worldwide, and it is the second leading cancer in terms of
mortality, with hepatocellular carcinoma (HCC) being the
most common subtype of primary liver cancer. The liver
cancer incidence in Eastern Asia is the highest in the
world.1 In both China and Japan, HCC is one of the most
common malignant tumors; however, in China, the pre-
dominant underlying liver disease of HCC is hepatitis B virus
infection, which differs from that found in Japan. Accord-
ing to a nationwide survey by the Liver Cancer Study Group
of Japan, although the proportion of hepatitis virus-related
HCC decreased in Japan between 2005 and 2015, the HBV
infection rate was 13.1%, and the HCV infection rate was
67.7%.2 Moreover, the incidence of nonBnonC-HCC more
than doubled during the same period, from 6.8% to 17.3%.2
Different etiological assessments and treatment methods
may result in different outcomes between China and Japan.
The main purpose of this study was to compare the
overall survival rates of patients who underwent curative
hepatectomy for HCC between China and Japan and to
identify the risk factors that affect the outcome of HCC
after curative hepatectomy. We used data collected from
two regional medical centers: Nagasaki University Hospital,
Nagasaki, Japan, and the Second Hospital affiliated of
Nanchang University, Nanchang, China. Nagasaki is the
capital and the largest city of Nagasaki Prefecture on the
island of Kyushu in Japan. As of January 1, 2009, the esti-
mated population was 446,007, and the total area covers
406.35 km2. Nanchang is the capital of Jiangxi Province in
southeastern China. As of 2010,w5,042,565 individuals live
in the prefecture, of which 2,357,838 live in an area
comprising all five urban districts. All chief leading surgeons
who made the decisions and performed surgery in both
facilities had > 15 years of hepatobiliary and pancreatic
surgical experience.
2. Materials and methods
2.1. Study setting and design
A retrospective review was conducted regarding the source
population in the patient-information database of the
Department of Surgery, Nagasaki University Hospital and
the Department of Hepatobiliary and Pancreatic Surgery,
Second Affiliated Hospital of Nanchang University. The
charts of all patients who had a HCC diagnosis confirmed byang K, et al., Comparison of the o
a and Japan, Asian Journal of Suhistopathology were examined for detailed data elements
that identified 200 patients (the Nagasaki group) and 238
patients (the Nanchang group) with HCC who had under-
gone curative hepatectomy with tumor-negative resection
margins (R0 resection) as a first-line antitumor treatment
between January 2005 and December 2014 in the two fa-
cilities. None of the patients had received presurgicalutcomes of hepatocellular carcinoma after hepatectomy between
rgery (2016), http://dx.doi.org/10.1016/j.asjsur.2016.03.002
Table 1 (continued )
Variable Nagasaki
group
(n Z 200)
Nanchang
group
(n Z 238)
p
Differentiation <0.001
Well 53 (26.5) 27 (11.3)
Moderate 119 (59.5) 162 (68.1)
Poor 19 (9.5) 37 (15.5)
Unknown 9 (4.5) 12 (5)
AJCC Stage 0.010
I 132 (66) 157 (66)
II 36 (18) 23 (9.7)
IIIa 13 (6.5) 14 (5.9)
IIIb 14 (7) 13 (5.5)
IIIc 4 (2) 28 (11.8)
IVa 1 (0.5) 3 (1.3)
IVb 0 0
Hepatectomy <0.001
Anatomical 139 (69.5) 103 (43.3)
Partial 61 (30.5) 135 (56.7)
Mortality at 30 d 2 (1.0) 3 (1.3) 0.261
Data are presented as n (%), unless otherwise indicated.
AFP Z alpha-fetoprotein; AJCC Z American Joint Committee
on Cancer; HBV Z hepatitis B virus; HCV Z hepatitis C virus;
NASHZ nonalcoholic steatohepatitis; SDZ standard deviation.
Figure 1 Overall survival after curative liver resection between t
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two regional medical centers in China and Japan, Asian Journal of Sucancer treatment or suffered from recurrence of HCC or
any other known malignancy, and HCC had not metasta-
sized to distant sites in any of the patients. The preoper-
ative clinical and postoperative pathologic characteristics
of the two groups are presented in Table 1. All patients
were evaluated for HCC stage according to the 7th edition
American Joint Committee on Cancer (AJCC) staging system
by a retrospective analysis.3 Ethical approval for our
research protocol was obtained from the institutional re-
view boards of both hospitals.2.2. Criteria for hepatectomy
The patients in the Nagasaki group had been clinically
evaluated and underwent curative hepatectomy according
to the Nagasaki criteria described by Hidaka et al.4 The
patients in the Nanchang group had been clinically evalu-
ated and underwent curative hepatectomy according to the
guidelines of HCC diagnosis and treatment described by the
Ministry of Health of the People’s Republic of China.5 All
pre-, intra-, and postoperative polices followed the guide-
lines of the respective country as previously described.4,5
In this study, we attempted to compare the long-term
outcomes of the patients in both institutions and identify
different disease backgrounds or clinicopathologic featureshe Nagasaki group and Nanchang group. OSZ overall survival.
utcomes of hepatocellular carcinoma after hepatectomy between
rgery (2016), http://dx.doi.org/10.1016/j.asjsur.2016.03.002
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to the operation.
2.3. Statistical analysis
Data were analyzed using SPSS version 19 (IBM, Armonk,
NY, USA). Continuous variables were expressed as medians
and ranges. All results were rounded to no more than three
significant figures as confirmed by our biostatistician.
Categorical variables were expressed as frequencies and
percentages. The ManneWhitney U test was used to
compare continuous variables between the two groups.Figure 2 Overall survival after curative liver resection between
stage. (A) OS of AJCC stage I comparison; (B) OS of AJCC stage II
AJCC Z American Joint Committee on Cancer; OS Z overall survi
Please cite this article in press as: Wang K, et al., Comparison of the o
two regional medical centers in China and Japan, Asian Journal of SuThe Chi-square or Fisher’s exact tests was used to compare
categorical variables between the two groups as appro-
priate. Cumulative overall survival rates were determined
using the KaplaneMeier method and compared using the
Cox regression model for univariate analysis. After uni-
variate analysis, only variables with p < 0.1 were included
in the multivariate analysis, which used the Cox propor-
tional hazard model to identify independent-survival pre-
dictors. Hazard ratios (HR) and 95% confidence intervals
(CI) were calculated. For all tests except the univariate
analysis, a p < 0.05 was considered to be statistically
significant.the Nagasaki group and Nanchang group stratified by the AJCC
comparison; and (C) OS of beyond-AJCC stage III comparison.
val.
utcomes of hepatocellular carcinoma after hepatectomy between
rgery (2016), http://dx.doi.org/10.1016/j.asjsur.2016.03.002
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Nagasaki group and the Nanchang group
There were significant differences in some clinicopatho-
logical variables between the two groups (Table 1). In both
groups, there were more male patients than female pa-
tients; however, in the Nagasaki group, the male/female
ratio was lower than that observed in the Nanchang group.
There were more patients who had high levels (> 400 U/L)
of serum alpha-fetoprotein (AFP) in the Nanchang group as
compared with the Nagasaki group. In the Nanchang group,
w51.7% of the patients had a large tumor
(diameter > 5 cm), whereas only 26% of the patients had a
large tumor in the Nagasaki group. More patients had un-
dergone anatomical hepatectomy in the Nagasaki group as
compared with the Nanchang group, and there was no dif-
ference in the Child-Pugh score or the 30-day mortality rate
between the two groups (p Z 0.261; Table 1).Table 2 Comparison of the clinicopathological charac-
teristics of AJCC stage I.
Variables Nagasaki Nanchang p
(n Z 132) (n Z 157)
Gender 0.077
Male 102 (77.3) 134 (85.4)
Female 30 (22.7) 23 (14.6)
Age (y) <0.001
<60 24 (18.2) 108 (71.7)
60 108 (81.8) 49 (31.2)
Underlying liver disease <0.001
HBV 29 (22) 129 (82.2)3.2. Overall survival rate analysis
The median follow-up times for the Nagasaki and Nanchang
groups were 39.4 months (interquartile range,
0.6e121.4 months) and 19.6 months (interquartile range,
0.4e111 months), respectively. In the outcome analysis,
the Nanchang group showed an overall worse survival rate
relative to the Nagasaki group (the 1-, 3-, and 5-year overall
survival rates were 75.7%, 62.9%, and 53.3% in the Nan-
chang group and 92.6%, 83.3%, and 73% in the Nagasaki
group, respectively; p < 0.05; Figure 1).HCV 42 (31.8) 0
NASH 52 (39.4) 8 (5.1)
Alcohol 8 (6.1) 0
HBV-HCV 0 1 (0.6)
HBV-Alcohol 0 19 (12.1)
HCV-Alcohol 1 (0.8) 0
AFP (ng/mL) <0.001
400 120 (90.9) 99 (63.1)
>400 12 (9.1) 58 (36.9)
Capsule <0.001
Present 101 (76.5) 145 (92.4)
Absent 31 (23.5) 12 (7.6)
Tumor size (cm) <0.001
5 110 (83.3) 84 (53.5)
>5 22 (16.7) 73 (46.5)
Differentiation 0.002
Well 34 (25.7) 22 (14)
Moderate 88 (66.7) 106 (67.5)
Poor 10 (7.6) 19 (12.1)
Unknown 0 10 (6.4)
Hepatectomy 0.001
Anatomical 88 (66.7) 75 (47.8)
Partial 44 (33.3) 82 (52.2)
Data are presented as n (%).
AFP Z alpha-fetoprotein; AJCC Z American Joint Committee
on Cancer; HBV Z hepatitis B virus; HCV Z hepatitis C virus;
NASH Z nonalcoholic steatohepatitis.3.3. Stratification and comparison of survival
according to the AJCC staging system
We compared the overall survival rates of patients in the
same AJCC stage between the two groups by dividing each
group into three levels: AJCC stage I, AJCC stage II, and
beyond-AJCC stage III. The overall survival rates of patients
with AJCC stage I and those beyond-AJCC stage III in the
Nagasaki group were better than those of patients in the
Nanchang group (Figures 2A and 2C).
We also compared the clinicopathologic characteristics
of AJCC stage I patients and those beyond-AJCC stage III
between the two groups. The results showed differences
between the two groups in the etiologies of patients in
these two different AJCC stages (Tables 2e4). Regarding
AJCC stage I, the patients tended to be older, had lower
serum AFP levels, absent capsule, smaller tumor size, and
better tumor differentiation in the Nagasaki group as
compared with the Nanchang group. Additionally, more
patients had undergone anatomical hepatectomy in the
Nagasaki group as compared with the Nanchang group.
Regarding the subgroup beyond-AJCC stage III, the patients
tended to be older and more frequently presented with
vascular invasion in the Nagasaki group as compared with
the Nanchang group. For both AJCC stage I and beyond-
AJCC stage III patients, more patients had undergonePlease cite this article in press as: Wang K, et al., Comparison of the o
two regional medical centers in China and Japan, Asian Journal of Suanatomical hepatectomy in the Nagasaki group as
compared with the Nanchang group.
There was no difference in the survival rates of patients
with AJCC stage II between the two groups (Figure 2B).
Additionally, among AJCC stage II patients, there were
significant differences in some variables between the two
groups, such as age, HCC etiology, and vascular invasion
(Table 3); however, there was no difference in the ratio of
patients who had undergone anatomical hepatectomy be-
tween the two groups (Table 3).3.4. Independent risks identified
In the Nagasaki group, a univariate analysis identified male
gender, serum AFP level > 400 U/L, absent tumor capsule,
and presence of vascular invasion to be significant predictors
of the survival of patients with HCC after resection (Table 5),
while in the Nanchang group (Table 6), a serum AFP
level > 400 U/L, larger tumor size (> 5 cm), vascularutcomes of hepatocellular carcinoma after hepatectomy between
rgery (2016), http://dx.doi.org/10.1016/j.asjsur.2016.03.002
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of survival. In the multivariate Cox proportional HR analysis,
male gender, serumAFP>400U/L, andabsent tumor capsule
were independent-risk factors of overall survival in the
Nagasaki group, whereas a larger tumor (> 5 cm), vascular
invasion, and poor differentiation were independent-risk
factors of overall survival in the Nanchang group.
4. Discussion
In East Asia, hepatitis virus infection is the most common
cause of HCC.6 However, there have been variations in the
subtype of hepatitis infection in different countries. InTable 3 Comparison of the clinicopathological charac-
teristics of AJCC stage II.
Variables Nagasaki
(n Z 36)
Nanchang
(n Z 23)
p
Gender 0.183
Male 26 (72.2) 20 (87)
Female 10 (27.8) 3 (13)
Age (y) <0.001
<60 30 (83.3) 15 (65.2)
60 6 (16.7) 8 (34.8)
Underlying liver disease <0.001
HBV 9 (25) 18 (78.3)
HCV 17 (47.2) 0
NASH 5 (13.9) 3 (13)
Alcohol 4 (11.1) 0
HBV-HCV 1 (2.8) 0
HBV-Alcohol 0 2 (8.7)
HCV-Alcohol 0 0
AFP (ng/mL) 0.647
400 27 (75) 16 (69.6)
>400 9 (25) 7 (30.4)
Capsule 0.080
Present 22 (61.1) 19 (82.6)
Absent 14 (38.9) 4 (14.4)
Tumor size (cm) 0.715
5 31 (86.1) 19 (82.6)
>5 5 (13.9) 4 (14.4)
Tumor numbers 0.025
3 34 (94.4) 17 (73.9)
>3 2 (5.6) 6 (26.1)
Vascular invasion <0.001
Present 20 (44.4) 0
Absent 16 (56.6) 23 (100)
Differentiation 0.099
Well 11 (30.6) 2 (8.7)
Moderate 19 (52.8) 18 (78.3)
Poor 6 (16.7) 3 (13)
Unknown 0 0
Hepatectomy 0.124
Anatomical 23 (63.9) 10 (43.5)
Partial 13 (36.1) 13 (56.5)
Data are presented as n (%).
AFP Z alpha-fetoprotein; AJCC Z American Joint Committee
on Cancer; HBV Z hepatitis B virus; HCV Z hepatitis C virus;
NASH Z nonalcoholic steatohepatitis.
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whereas in Japan, HCV infection is more common than
HBV infection.6 Furthermore, the number of nonBnonC-HCC
patients has recently increased in Japan.8 Although the
epidemiologic analyses and clinical series have led to a
better understanding of the behavior and natural history of
HCC, these studied do not typically subanalyze the results
according to the underlying liver disease; therefore, vari-
ations in the patterns of presentation, tumor biology, or
treatment outcomes for HCC according to the underlying
disease remain unclear.2,6,9 According to the data pre-
sented here, we found that there were significant differ-
ences in the etiology between the population of HCCTable 4 Comparison of the clinicopathological charac-
teristics of beyond-AJCC stage III.
Variables Nagasaki
(n Z 32)
Nanchang
(n Z 58)
p
Gender 0.136
Male 25 (78.1) 52 (89.7)
Female 7 (21.9) 6 (11.3)
Age (y) <0.001
<60 11 (34.4) 43 (74.1)
60 21 (65.6) 15 (25.9)
Underlying liver disease <0.001
HBV 14 (43.8) 42 (72.4)
HCV 5 (15.6) 0
NASH 12 (37.5) 3 (5.2)
Alcohol 0 1 (1.7)
HBV-HCV 0 0
HBV-Alcohol 1 (3.1) 12 (20.7)
HCV-Alcohol 0 0
AFP (ng/mL) 0.299
400 18 (56.3) 26 (44.8)
>400 14 (43.8) 32 (55.2)
Capsule 0.152
Present 23 (71.9) 49 (84.5)
Absent 9 (28.1) 9 (15.5)
Tumor size (cm) 0.895
5 7 (21.9) 12 (20.7)
>5 25 (78.1) 46 (79.3)
Tumor numbers 0.106
3 31 (96.9) 50 (86.2)
>3 1 (3.1) 8 (13.8)
Vascular invasion 0.009
Present 19 (59.4) 20 (34.5
Absent 13 (40.6) 38 (65.5)
Differentiation 0.011
Well 9 (28.1) 3 (5.2)
Moderate 19 (59.4) 38 (65.5)
Poor 4 (12.5) 15 (25.9)
Unknown 0 2 (3.4)
Hepatectomy <0.001
Anatomical 28 (87.5) 18 (31)
Partial 4 (12.5) 40 (69)
Data are presented as n (%).
AFP Z alpha-fetoprotein; AJCC Z American Joint Committee
on Cancer; HBV Z hepatitis B virus; HCV Z hepatitis C virus;
NASH Z nonalcoholic steatohepatitis.
utcomes of hepatocellular carcinoma after hepatectomy between
rgery (2016), http://dx.doi.org/10.1016/j.asjsur.2016.03.002
Table 5 Cox proportional HR analyses for overall survival in the Nagasaki group.
Variables n Univariate analysis Multivariate analysis
HR (95% CI) p HR (95% CI) p
Age (y) 0.417
<60 41 1
60 159 1.324 (0.672e2.610)
Gender 0.036 0.015
Male 153 1 1
Female 47 0.334 (0.120e0.932) 0.279 (0.099e0.780)
Underlying liver disease 0.576
HBV 52 1
HCV 64 0.125 (0.016e0.997)
NASH 69 0.121 (0.016e0.943)
Alcohol 12 0.170 (0.022e1.300)
HBV-HCV 1 0.156 (0.016e1.531)
HBV-Alcohol 1 0
HCV-Alcohol 1 0
Child-Pugh 0.313
A 188 1
B 12 1.7 (0.607e4.762)
AFP level (ng/mL) 0.005 0.001
400 165 1 1
>400 35 2.615 (1.331e5.135) 2.995 (1.522e5.896)
Tumor size (cm) 0.166
5 148 1
>5 52 1.587 (0.825e3.053)
Tumor numbers 0.309
3 197 1
>3 3 0.355 (0.048e2.614)
Tumor capsule 0.064 0.031
Present 146 1 1
Absent 54 1.778 (0.968e3.268) 1.962 (1.065e3.616)
Vascular invasion 0.014 0.155
Absent 159 1 1
Present 41 2.201 (1.173e4.128) 1.682 (0.821e3.446)
Differentiation 0.568
Well
Moderate 54 1
Poor 126 1.474 (0.702e3.094)
Unknown 20 1.546 (0.517e4.620)
Hepatectomy 0.683
Anatomical 139 1
Partial 61 0.877 (0.466e1.649)
AFP Z alpha-fetoprotein; AJCC Z American Joint Committee on Cancer; CI Z confidence interval; HBV Z hepatitis B virus;
HCV Z hepatitis C virus; HR Z hazard regression; NASH Z nonalcoholic steatohepatitis.
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66% of the patients had nonBnonC or HCV-related HCC.
Conversely, these infections were rare in the Nanchang
group. However, the etiology was not an independent-risk
factor of overall survival for either group.
In this study, the overall survival rates of the Nagasaki
group were better as compared with those in the Nanchang
group. According to the results of univariate and multivar-
iate analyses, the two groups exhibited different
independent-risk factors for overall survival. We initially
noted that there were more patients with larger tumors in
the Nanchang group as compared with the Nagasaki group.
We also found that anatomical hepatectomies were morePlease cite this article in press as: Wang K, et al., Comparison of the o
two regional medical centers in China and Japan, Asian Journal of Sufrequently performed in patients with larger tumors
(diameter > 5 cm) in the Nagasaki group (49/52, 94.2%) as
compared with those in the Nanchang group (31/123,
25.2%), and, interestingly, the overall survival rate in the
Nagasaki group was significantly better than that observed
in the Nanchang group. Previous results indicated that
anatomical hepatectomy conveyed a survival advantage
over non-anatomical hepatectomy in HCC patients with
tumors measuring < 5 cm in diameter.10,11 We also found
that in our patients with smaller tumor sizes
(diameter  5 cm), the survival rates were not significantly
different between the two groups, because anatomical
hepatectomy was performed at a similar rate in bothutcomes of hepatocellular carcinoma after hepatectomy between
rgery (2016), http://dx.doi.org/10.1016/j.asjsur.2016.03.002
Table 6 Cox proportional HR analyses for overall survival in the Nanchang group.
Variables n Univariate analysis Multivariate analysis
HR (95% CI) p HR (95% CI) p
Age (y) 0.829
<60 166 1
60 72 0.95 (0.594e1.518)
Gender 0.652
Male 206 1
Female 32 1.164 (0.601e2.255)
Underlying Liver disease 0.884
HBV 189
HCV 0
NASH 14 1
Alcohol 1 1.282 (0.555e2.961)
HBV-HCV 1 0
HBV-Alcohol 33 2.474 (0.342e17.877)
HCV-Alcohol 0 1.114 (0.587e2.112)
Child-Pugh 0.392
A 225 1
B 13 0.392 (0.096e1.596)
AFP level (ng/mL) 0.005 0.184
400 141 1 1
>400 97 1.843 (1.197e2.838) 1.359 (0.864e2.136)
Tumor size (cm) <0.001 0.028
5 115 1 1
>5 123 2.376 (1.493e3.781) 1.721 (1.061e2.792)
Tumor numbers 0.174
3 224 1
>3 14 1.785 (0.775e4.114)
Tumor capsule 0.857
Present 213 1
Absent 25 1.066 (0.533e2.130)
Vascular invasion <0.001 0.003
Absent 219 1 1
Present 19 3.817 (2.133e6.830) 2.522 (1.369e4.645)
Differentiation <0.001 <0.001
Well 27 1 1
Moderate 162 3.071 (0.953e9.899) 2.840 (0.878e9.819)
Poor 37 11.309 (3.400e37.620) 8.435 (2.498e28.480)
Unknown 12 7.755 (2.097e28.683) 6.343 (1.698e23.697)
Hepatectomy 0.062 0.564
Anatomical 103 1 1
Partial 135 1.531 (0.978e2.395) 1.152 (0.712e1.863)
AFP Z alpha-fetoprotein; AJCC Z American Joint Committee on Cancer; CI Z confidence interval; HBV Z hepatitis B virus;
HCV Z hepatitis C virus; HR Z hazard regression; NASH Z nonalcoholic steatohepatitis.
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+ MODELgroups. Our results further suggested that anatomical
hepatectomy may result in a survival benefit, even in HCC
patients with larger tumors.
The AJCC staging system for HCC based on the objective
situation of the patient, such as tumor size, tumor number,
status of vascular invasion, local invasion, lymph nodes,
and distant organ metastasis, was demonstrated to be an
effective prognostic and evaluation system for the outcome
of HCC patients, particularly those in the early stages.3
However, another group suggested that the AJCC staging
system, irrespective of the degree of liver damage and
level of liver function, provides an inferior ability toPlease cite this article in press as: Wang K, et al., Comparison of the o
two regional medical centers in China and Japan, Asian Journal of Suevaluate the prognosis of HCC patients.12e14 Therefore,
conflicting results remain.15,16 In this study, we found that
patients with AJCC stage I had greater survival benefits
relative to those with AJCC stage II and beyond stage III.
Comparing the overall survival rates of patients in
different AJCC stages between the two groups, we found
that patients in the Nagasaki groups exhibited a better
survival rate, except for patients in AJCC stage II. According
to the results of the clinicopathologic-characteristics
comparison, we found more significantly different vari-
ables between AJCC stage I and beyond-AJCC stage III pa-
tients as compared to patients in AJCC stage II. We furtherutcomes of hepatocellular carcinoma after hepatectomy between
rgery (2016), http://dx.doi.org/10.1016/j.asjsur.2016.03.002
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+ MODELperformed propensity score matching (data not shown) and
found that the outcomes were similar when we balanced
the baseline.
Unfortunately, due to complicated socioeconomic rea-
sons, the management of recurrent HCC was heterogenized
in China; therefore, a precise therapeutic procedure was
lacking during the management of recurrent HCC in the
Nanchang group despite the fact that treatment after
recurrence affects survival.
The overall 30-day mortality of the entire cohort is
shown in Table 1. Since the 30-day mortality rate did not
differ between the two institutions, there should not have
been a large difference in the surgical technique and
strategy. Additionally, the size of the two cities indicates
that both institutions were the primary tertiary referral
hospital in their respective areas.
In conclusion, significant differences in the clinicopath-
ologic features and outcomes existed among HCC patients
in two different East Asian countries. These differences
have an impact on the eligibility to receive potentially
curative therapy and the subsequent prognosis of patients
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